Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Ann Thorac Surg ; 77(6): 1883-90, 2004 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15172229

RESUMEN

BACKGROUND: Because biological behavior in lung tumors with neuroendocrine differentiation is highly dependent on cell death (apoptosis) and angiogenesis, p21(waf1/cip1) and microvessel density have been targeted as potentially useful tumor markers. We sought to validate the importance of p21(waf1/cip1) and microvessel density and study their interrelationship, analyzing clinical factors, subclassifications, and tumor and stromal markers. METHODS: We examined p21(waf1/cip1) and other markers in tissue from 61 patients with surgically excised large cell carcinomas. The amount of tumor staining for p21(waf1/cip1) and microvessel density was evaluated by immunohistochemistry and morphometry. The study outcome was survival time until death from recurrent lung cancer. RESULTS: Multivariate Cox model analysis demonstrated that after surgical excision, histologic subtypes were significantly related to survival time (p = 0.02), but quantitative staining of the tumor for p21(waf1/cip1) and microvessel density added prognostic information and these variables were more strongly prognostic than histologic subtype (p = 0.00). Cut points at the median staining of 3.5% and 3.0% for p21(waf1/cip1) and microvessel density, respectively, divided patients into two groups with distinctive survival times. Patients with p21(waf1/cip1) staining of more than 3.5% and microvessel density staining of more than 3.0% had a median survival time of 14 months. CONCLUSIONS: Tumor staining for p21(waf1/cip1) and microvessel density in resected large cell carcinomas and certain other types of lung tumors was strongly related to survival. Patients with more than 3.0% staining in their tumors were at high risk of death from lung cancer and may be an appropriate target for prospective studies of adjuvant chemotherapy after surgical resection.


Asunto(s)
Carcinoma de Células Grandes/patología , Carcinoma Neuroendocrino/patología , Neoplasias Pulmonares/patología , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma de Células Grandes/química , Carcinoma de Células Grandes/mortalidad , Carcinoma Neuroendocrino/química , Carcinoma Neuroendocrino/mortalidad , Inhibidor p21 de las Quinasas Dependientes de la Ciclina , Ciclinas/análisis , Ciclooxigenasa 2 , Femenino , Humanos , Inmunohistoquímica , Isoenzimas/análisis , Neoplasias Pulmonares/química , Neoplasias Pulmonares/mortalidad , Masculino , Metaloproteinasa 9 de la Matriz/análisis , Proteínas de la Membrana , Persona de Mediana Edad , Modelos de Riesgos Proporcionales , Prostaglandina-Endoperóxido Sintasas/análisis , Estudios Retrospectivos , Tasa de Supervivencia , Proteína p53 Supresora de Tumor/análisis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA